Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | GRK2 | P25098 | 6/20 | 0.38 |
| ▸ | GRK5 | P34947 | 1/20 | 0.38 |
| ▸ | GRK3 | P35626 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5329635 | 0.86 | GRK2 (0.55) | GRK2GRK5GRK3ROCK2ROCK1 | |
| SCHEMBL5537921 | 0.80 | GRK2 (0.39) | GRK2GRK5GRK3ROCK2KDM4E | |
| SCHEMBL5539705 | 0.75 | GRK2 (0.56) | GRK2GRK5GRK3ROCK2GAA | |
| SCHEMBL5533048 | 0.75 | CA1 (0.57) | GRK2GRK5GRK3ROCK2CA12 | |
| SCHEMBL5536140 | 0.74 | CYP17A1 (0.47) | CYP17A1GRK2GRK5GRK3ROCK2 | |
| SCHEMBL5535879 | 0.74 | GRK2 (0.57) | GRK2GRK5GRK3ROCK2KDM4E | |
| SCHEMBL5545993 | 0.72 | GRK2 (0.59) | GRK2GRK3ROCK2ROCK1L3MBTL1 | |
| SCHEMBL5537408 | 0.70 | GRK2 (0.43) | GRK2GRK5GRK3ROCK2MEN1 | |
| SCHEMBL14496401 | 0.68 | GRK2 (0.75) | GRK2GRK5GRK3ROCK2GAA | |
| SCHEMBL10836457 | 0.66 | POLB (0.60) | CYP17A1GAAKDM4EROCK1MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135499-A1 | Hydrazide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135499-A1 | Hydrazide compounds | GRK4, GRK2, GRK1 | CYP17A1 3491/4885GRK2 2/4885GRK5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.